# Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

> **NCT01231503** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 480 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GSK Biological's Investigational Malaria Vaccine 257049
- **BIOLOGICAL:** Engerix-B
- **BIOLOGICAL:** Tritanrix HepB Hib
- **BIOLOGICAL:** BCG
- **BIOLOGICAL:** OPV
- **BIOLOGICAL:** Rouvax

## Key facts

- **NCT ID:** NCT01231503
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-13
- **Primary completion:** 2014-04-30
- **Final completion:** 2014-12-23
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2018-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231503, "Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01231503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*